Vol. 5 No. 4 (2026), Articles
Vol. 5 No. 4 (2026)

YUQORI TUZ ISTE’MOLI VA SUV YETISHMOVCHILIGINING ARTERIAL GIPERTENZIYA HAMDA SURUNKALI BUYRAK KASALLIGI RIVOJLANISHIDAGI PATOGENETIK AHAMIYATI

Articles
Published 2026-08-27
Tursunova Laylo Dilshotovna
TTA 2-son fakultet va gospital terapiya, nefrologiya va gemodializ kafedrasi dotsenti, DSc
Qilichov Sherbek Alisher oʻgʻli
Toshkent Tibbiyot Akademiyasi magistratura bosqichi
PDF

Keywords

arginin vazopressin, copeptin, arterial gipertenziya, surunkali buyrak kasalligi, natriy homeostazi, suv balansi.

Abstract

Arterial gipertenziya va surunkali buyrak kasalligi dunyo miqyosida kasallanish va o‘limning asosiy sabablaridan biri hisoblanadi. So‘nggi yillarda natriy va suv gomeostazini boshqaruvchi mexanizmlar haqidagi bilimlar sezilarli darajada kengaydi. Ushbu maqolada yuqori tuz iste’moli va suv yetishmovchiligining arterial gipertenziya hamda surunkali buyrak kasalligi rivojlanishidagi patogenetik mexanizmlari tahlil qilindi. Zamonaviy tadqiqotlar natriy va suv balansining buzilishi arginin vazopressin (AVP) sekretsiyasining ortishiga olib kelishini, bu esa buyraklarda natriy va suvning qayta so‘rilishini kuchaytirib, glomerulyar gipertenziya, proteinuriya va buyrak funksiyasining pasayishiga sabab bo‘lishini ko‘rsatmoqda. Bundan tashqari, teri va mushaklarda osmotik bo‘lmagan natriy zaxiralari mavjudligi hamda ularning rezistent arterial gipertenziya bilan bog‘liqligi aniqlangan. Tuz iste’molini cheklash va suyuqlik qabul qilishni oshirish yurak-qon tomir va buyrak kasalliklari profilaktikasida muhim ahamiyatga ega.

PDF

References

Titze J., Luft F.C. Speculations on salt and the genesis of arterial hypertension. Kidney International. 2017;91(6):1324–1335.

2. Bankir L., Bichet D.G., Morgenthaler N.G. Vasopressin: physiology, assessment and clinical implications. Nature Reviews Nephrology. 2017;13(10):605–622.

3. Torres V.E., Chapman A.B., Devuyst O. et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. New England Journal of Medicine. 2017;377(20):1930–1942.

4. Kuwabara M., Hisatome I., Niwa K. et al. Serum sodium concentration and risk of chronic kidney disease. American Journal of Medicine. 2020;133(4):e123–e132.

5. Ponte B., Pruijm M., Ackermann D. et al. Copeptin, kidney disease and hypertension. Nephrology Dialysis Transplantation. 2018;33(2):300–307.

6. Bankir L., Bouby N., Ritz E. Vasopressin: a novel target for slowing progression of chronic kidney disease? Nature Reviews Nephrology. 2013;9(4):223–239.

7. Titze J. A different view on sodium balance. Current Opinion in Nephrology and Hypertension. 2015;24(1):14–20.

8. He F.J., MacGregor G.A. Salt reduction lowers cardiovascular risk: meta-analysis of outcome trials. Lancet. 2020;395(10242):1623–1634.